Magnesium in metabolic syndrome: a review based on randomized, double-blind clinical trials
Guerrero-Romero F, Jaquez-Chairez FO, Rodríguez-Morán M
Magnesium research · 25 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Systematic review (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2016-04-01 · Magnes Res · vol. 29 · issue 4 · pp. 146–153
- Publisher
- John Libbey Eurotext
- Cited
- 44 citations · more than 88% of similar papers · 2.3× the field average
- References
- 0 works
- Access
- Paywalled
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments
- Keywords
- Medicine, Hypomagnesemia, Randomized controlled trial, Internal medicine, Blood pressure, Type 2 diabetes, Blinding, Metabolic syndrome, Crossover study, Clinical trial, Diabetes mellitus, Endocrinology, Magnesium, Placebo, Pathology, Chemistry
- MeSH
- humans, magnesium, double-blind method, randomized controlled trials as topic, metabolic syndrome
3 authors
From MX
- Fernando Guerrero‐RomeroMexican Social Security Institute
- Francia O Jaquez-ChairezMexican Social Security Institute
- Martha Rodríguez‐MoránMexican Social Security Institute
Abstract
A growing body of evidence shows the effect of magnesium on serum glucose, HDL-cholesterol, and triglycerides levels, as well as on blood pressure, which strongly suggests that magnesium might play an important role in metabolic syndrome (MetS), a cluster of risk factors for cardiovascular disease and type 2 diabetes. We performed a systematic review of clinical evidence derived from randomized, double-blind, controlled clinical trials, regarding the efficacy of magnesium supplementation on the components of MetS. Using the electronic databases of Medline, Embase, and the Cochrane Controlled Trials Register up to May 2016, we looked for randomized controlled trials focused on the effects of oral magnesium supplementation on insulin sensitivity, glucose, triglyceride and HDL-cholesterol levels, as well as its effects on high blood pressure, irrespective of the magnesium salt used, and with a duration of at least four weeks. Crossover studies, irrespective of blinding criteria, were not included. Results of this review show that magnesium supplementation in individuals with hypomagnesemia can be effective in the treatment of MetS.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.